前药
药理学
双氢青蒿素
活性氧
己酮可可碱
体内
肉桂醛
氧化应激
炎症
化学
氧化磷酸化
癌症研究
甘草甜素
和厚朴酚
体外
毒性
非酒精性脂肪肝
药物输送
联合疗法
医学
巨噬细胞
生物化学
干扰素基因刺激剂
作者
Ru Hao,Yu Sun,Changyuan Wang,Yang Wang,Lei Li,Huijun Sun,Lixue Chen
标识
DOI:10.1021/acsami.5c22301
摘要
The treatment of nonalcoholic steatohepatitis (NASH) has long been challenging due to its complex and heterogeneous pathogenesis. The NASH disease process is rooted in dysregulation caused by oxidative stress, where the overproduction of reactive oxygen species (ROS) exacerbates disease progression. To address these issues, we developed a ROS-sensitive prodrug containing dihydroartemisinin (DHA) and cinnamaldehyde (CA). By application of a thin-film hydration method, the synthetic prodrug was encapsulated with TPGS and Soluplus to prepare nanomicelles (DHA-CA@NMs). Furthermore, the formed nanomicelles allowed for targeted delivery to inflammatory sites with high ROS production. In NASH tissue, the elevated ROS cleaved the ROS-sensitive linker in the DHA-CA prodrugs to release DHA and CA, then exerting anti-inflammatory effects and ameliorating the inflammatory microenvironment. The results from experiments indicated that DHA-CA@NMs achieved amelioration of hepatic inflammation through the suppression of macrophage polarization, preventing oxidative stress, counteracting ferroptosis, and suppressing NF-κB pathway activation. Furthermore, in vivo studies confirmed that DHA-CA@NMs exhibited excellent biosafety and therapeutic efficacy against the mice with methionine- and choline-deficient (MCD) diet-induced NASH. These findings suggest the potential of the DHA-CA@NMs nanotherapeutic system for treating NASH.
科研通智能强力驱动
Strongly Powered by AbleSci AI